ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Go back to ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 11.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.83 | 52 Week High | $2.18 | |||
| Open | $11.83 | 52 Week Low | $0.30 | |||
| Day High | $11.83 | P/E | N/A | |||
| Day Low | $11.83 | EPS | $-3.32 | |||
| Volume | 4,208 | |||||
